2025
Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams E, Gaffey S, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol N, Chiang A. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications 2025, 44: 101446. PMID: 40027276, PMCID: PMC11869879, DOI: 10.1016/j.conctc.2025.101446.Peer-Reviewed Original ResearchCirculating tumor DNAClinico-genomic datasetsRecurrent metastatic non-small cell lung cancerExtensive-stage small-cell lung cancerLung cancerMetastatic non-small cell lung cancerStandard line of therapyCirculating tumor DNA testingSmall-cell lung cancerNon-small cell lung cancerLines of therapyCell lung cancerClinico-genomic databaseSerial blood samplesPre-specified timepointsCommunity-based research sitesTumor DNAPatient cohortClinical dataStage IVGenomic profilingPrognostic biomarkerAcademic centersUS sitesBlood samples
2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman R, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd G, Harris L, Isaacs C, Dees C, Perou C, Johnson G, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover D, Ramaswamy B. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Research And Treatment 2024, 210: 179-189. PMID: 39644403, DOI: 10.1007/s10549-024-07551-z.Peer-Reviewed Original ResearchMetastatic triple negative breast cancerProgression-free survivalCirculating tumor DNATriple negative breast cancerTrametinib monotherapyNegative breast cancerStable diseasePartial responseBreast cancerCirculating tumor DNA clearanceMedian progression-free survivalClinical benefit rateMEK inhibitor trametinibPhase II studyBiomarkers of responseTreated with chemotherapyPotential early biomarkersInhibitor trametinibOpen-labelOverall survivalConclusionIn patientsDevelopment of resistanceObjective responseTumor DNABenefit rateMolecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations
Yasin F, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Zhang J, Ross J, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. The Oncologist 2024, 29: 1059-1067. PMID: 39401325, PMCID: PMC11630746, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchAdvanced colorectal cancerPIK3CA mutationsColorectal cancerPI3K inhibitionPI3K inhibitorsBurden of colorectal cancerActivating mutationsResponse to PI3K inhibitionSensitive to PI3K inhibition.Foundation Medicine databaseMetastatic colorectal cancerClinically relevant mutationsMicrosatellite instability-highPI3K signalingTumor DNAPIK3CA variantsClinical carePIK3CA oncogeneClinical variablesE545KGenomic profilingPIK3CAE542KMedicine DatabasePatientsImplementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective
Breadner D, Hwang D, Husereau D, Cheema P, Doucette S, Ellis P, Kassam S, Leighl N, Maziak D, Selvarajah S, Sheffield B, Juergens R. Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective. Current Oncology 2024, 31: 6017-6031. PMID: 39451753, PMCID: PMC11505603, DOI: 10.3390/curroncol31100449.Peer-Reviewed Original ResearchNon-small-cell lung cancerAdvanced non-small-cell lung cancerCirculating tumor DNALung cancerMolecular profilingLiquid biopsyImplementation of liquid biopsiesComprehensive molecular profilingNon-small-cellHigh-risk patientsCancer-related deathsMinimally invasive methodTissue biopsy samplesTumor DNAInsufficient tissueMultidisciplinary working groupTherapy selectionTissue biopsiesBiomarker testingBiopsy samplesBiopsyGold standardInvasive methodEligibility criteriaCancerEP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer
Peleg A, de la Fuente R, Lichtman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Rohs N, Smith C, Rolfo C. EP.06D.04 Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s502-s503. DOI: 10.1016/j.jtho.2024.09.932.Peer-Reviewed Original ResearchCirculating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. PMID: 40027305, PMCID: PMC11863946, DOI: 10.1016/j.jlb.2024.100168.Peer-Reviewed Original ResearchTriple negative breast cancerResidual cancer burdenCirculating tumor DNANegative breast cancerPathological responsePost-NACBreast cancerPlasma circulating tumor DNATriple negative breast cancer patientsResidual cancer burden scoreCirculating tumour DNA fractionPost-neoadjuvant chemotherapyPre-NAC samplesWeekly nab-paclitaxelTumor DNA methylation profilesTumor DNA fractionHot spot mutationsYouden's J statisticNab-paclitaxelPre-NACTumor variantsTumor DNATumor fractionClinical trialsDNA methylation profilesTislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, Cui Y, Li W, Li Q, Yu S, Feng Y, Liu Q, Yang Y, Zhang J, Xu F, Yu Y, Liu T. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications 2024, 15: 7255. PMID: 39179622, PMCID: PMC11343749, DOI: 10.1038/s41467-024-51536-x.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerVariant allele frequencyPhase 2 studyEpidermal growth factor receptorAdverse eventsRAS wild-type metastatic colorectal cancerRAS wt metastatic colorectal cancerSingle-arm phase 2 studyWild-type metastatic colorectal cancerColorectal cancerTreatment-related adverse eventsAnti-PD-1Disease control rateProgression-free survivalRAS wild-typeTumor immune responseCombined treatment regimenWild-typeGrowth factor receptorIrinotecan combinationOverall survivalAnti-EGFRPrimary endpointTumor DNASingle-armUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAWhole-genome sequencingCell-free DNAGenome sequenceDetection of molecular residual diseaseCirculating tumor DNA detectionResidual disease detectionConsistent with clinical outcomesVariant allele frequencyResidual diseaseMelanoma patientsMonitoring immunotherapyTumor DNAEsophageal cancerClinical outcomesColorectal cancerWGS technologiesAllele frequenciesCancerDNAAnalytical sensitivitySequenceImmunotherapyRelapseCirculating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Choi Y, Dharia N, Jun T, Chang J, Royer-Joo S, Yau K, Assaf Z, Aimi J, Sivakumar S, Montesion M, Sacher A, LoRusso P, Desai J, Schutzman J, Shi Z, group A. Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. Clinical Cancer Research 2024, 30: of1-of10. PMID: 38995268, PMCID: PMC11369623, DOI: 10.1158/1078-0432.ccr-24-0255.Peer-Reviewed Original ResearchConceptsKRAS G12C mutationTumor fractionSolid tumorsTumor typesG12C mutationOn-treatment time pointsNon-small cell lung cancerMutational heterogeneityAssociated with tumor typeProgression-free survivalPlasma samplesPhase 1 studyCell lung cancerCycle 1 dayAssociated with patient outcomesVariant allele frequencyAssociated with responseCtDNA levelsCtDNA profilingMetastatic sitesTruncal mutationsTumor DNATreatment responseLung cancerTumor tissuesCirculating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications
Gerke M, Jansen C, Bilen M. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers 2024, 16: 2280. PMID: 38927984, PMCID: PMC11201475, DOI: 10.3390/cancers16122280.Peer-Reviewed Original ResearchRenal cell carcinomaGU cancersProstate cancerBladder cancerGenitourinary (GU) cancersUtilization of liquid biopsyCastration-resistant prostate cancerDetect residual diseaseCirculating tumor DNATherapeutic response predictionCtDNA assaysResidual diseaseCtDNA analysisCell carcinomaTumor DNAGenitourinary cancersPrognostic informationClinical detection methodsTreatment responseGenomic alterationsLiquid biopsyClinical trialsTherapeutic implicationsCancerCtDNACirculating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNARecurrence-free survivalColorectal cancerMRD assaysDetection of molecular residual diseaseLevels of circulating tumor DNAPoor recurrence-free survivalTreated with curative intentDetect circulating tumor DNAProspective cohort of patientsCurative interventionsCurative-intent treatmentCohort of patientsSingle nucleotide variantsStage I-IIISeparation of patientsMRD- patientsMRD testingNeoadjuvant treatmentResidual diseaseClinical recurrenceCurative intentRectal cancerTumor DNAA phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.
Mukohara T, Park Y, Sommerhalder D, Yonemori K, Kim S, Kim J, Iwata H, Yamashita T, Layman R, Kim G, Im S, Lindeman G, Rugo H, Liyanage M, Homji Mishra N, Maity A, Bogg O, Liu L, Li M, LoRusso P. A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer. Journal Of Clinical Oncology 2024, 42: 3006-3006. DOI: 10.1200/jco.2024.42.16_suppl.3006.Peer-Reviewed Original ResearchHER2- metastatic breast cancerTreatment-related adverse eventsMetastatic breast cancerCirculating tumor DNABreast cancerGene mutationsFrequent treatment-related adverse eventsMedian duration of follow-upAntitumor activityDuration of follow-upClinical benefit rateProgression-free survivalHER2 breast cancerMutant allele frequencyExpansion doseFulvestrant combinationMedian DoRESR1 mutationsMetastatic settingDose modificationEndocrine therapySystemic therapyMedian durationTumor DNACDK4/6 inhibitorsMulti-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers
Belmont E, Bansal V, Yousef M, Zeineddine M, Su D, Dhiman A, Liao C, Polite B, Eng O, Fournier K, White M, Turaga K, Shen J, Shergill A. Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers. JCO Precision Oncology 2024, 8: e2300531. PMID: 38723230, DOI: 10.1200/po.23.00531.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAComplete cytoreductive surgeryCirculating tumor DNA detectionAppendiceal cancerPeritoneal metastasisGrade 2Systemic therapyTumor DNAComplete CRSAssociated with shorter recurrence-free survivalCirculating tumor DNA testingShorter recurrence-free survivalSystemic therapy responseRecurrence-free survivalDiagnosis of recurrenceDetection of recurrenceMulti-institutional studyCytoreductive surgerySystemic chemotherapyCA19-9Elevated biomarkersTherapy responseCtDNA detectionSpecialized centersCarcinoembryonic antigenLiquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy S, Eder J, Deng Y, LoRusso P, Kim J, Patel A. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO Precision Oncology 2024, 8: e2300289. PMID: 38412387, PMCID: PMC10914240, DOI: 10.1200/po.23.00289.Peer-Reviewed Original ResearchConceptsCell-free circulating tumor DNANon-small-cell lung cancerSmall-cell lung cancerTriple-negative breast cancerPancreatic ductal adenocarcinomaAdvanced solid tumorsVariant allele fractionRadiographic responseOverall survivalCombination therapySolid tumorsCtDNA levelsLung cancerPretreated advanced solid tumorsDays of combination therapyMetastatic pancreatic ductal adenocarcinomaResponse to anticancer therapyAssociated with disease progressionProgression-free survivalPlasma samplesLead-inPoly(ADP-riboseInferior OSTumor DNASurvival outcomesSearching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA)
Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R, Isakoff S, Bardia A, Peppercorn J. Searching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). Breast Cancer Research And Treatment 2024, 205: 211-226. PMID: 38355821, DOI: 10.1007/s10549-024-07253-6.Peer-Reviewed Original ResearchConceptsCirculating tumor DNABreast cancer careSystemic therapyTumor DNABreast cancerBreast cancer recurrence riskRisk of recurrenceCancer careCancer recurrence riskCirculating tumor cellsNarrative reviewTreat many patientsBreast cancer evaluationDistant diseaseFear of recurrenceBreast oncologistsPredictive biomarkersRecurrence riskTumor cellsCancer evaluationImprove prognosticationClinical challengeTreatment selectionPatientsBreast
2023
Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials
Rosen E, Schonhoft J, Silverman I, Yablonovitch A, Sethuraman S, Nejad P, Ulanet D, Yang J, Kim I, Fei K, Xu Y, Lagow E, Zhang S, Cai M, Koehler M, Carneiro B, Lheureux S, Cecchini M, Herzberg B, Reis-Filho J, Rimkunas V, Yap T. Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials. Molecular Cancer Therapeutics 2023, 22: a123-a123. DOI: 10.1158/1535-7163.targ-23-a123.Peer-Reviewed Original ResearchCirculating tumor DNAVariant allele frequencyDNA damage repairEpigenomic profilingTumor DNADamage repairResponse monitoringCirculating tumor DNA sequencingLow variant allele frequencyTreated with PARPiPhase 1 studyCell-free DNAMolecular responseIntragenic deletionsEpigenetic analysisAllele frequenciesRad3-relatedCH variantsGenomic alterationsOn-treatmentClinical outcomesPancreatic cancerAtaxia telangiectasiaPathogenic alterationsEvaluable ptsPerformance of Circulating Tumor DNA (ctDNA) Genomic and Epigenomic Profiling (GuardantINFINITY) in the TRESR and ATTACC Studies
Silverman I, Schonhoft J, Yablonovitch A, Lagow E, Cecchini M, Herzberg B, Reis-Filho J, Rosen E, Rimkunas V, Yap T. Performance of Circulating Tumor DNA (ctDNA) Genomic and Epigenomic Profiling (GuardantINFINITY) in the TRESR and ATTACC Studies. The Journal Of Liquid Biopsy 2023, 1: 100014. DOI: 10.1016/j.jlb.2023.100014.Peer-Reviewed Original ResearchTumor DNAEpigenomic profiling593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts)
Loh J, Choo J, Sooi K, Low P, Ang C, Sundar R, Walsh R, Wijaya S, Low J, Hsing S, Jain S, Chee C. 593P Role of circulating tumor DNA (ctDNA) in assessing primary anti–epidermal growth factor receptor (EGFR) resistance in untreated RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) patients (pts). Annals Of Oncology 2023, 34: s429. DOI: 10.1016/j.annonc.2023.09.1784.Peer-Reviewed Original ResearchSingle-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher A, LoRusso P, Patel M, Miller W, Garralda E, Forster M, Santoro A, Falcon A, Kim T, Paz-Ares L, Bowyer S, de Miguel M, Han S, Krebs M, Lee J, Cheng M, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin M, Royer-Joo S, Chang J, Dharia N, Schutzman J, Desai J. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. New England Journal Of Medicine 2023, 389: 710-721. PMID: 37611121, DOI: 10.1056/nejmoa2303810.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalTreatment-related adverse eventsProgression-free survivalAdverse eventsSolid tumorsG12C mutationLow-grade adverse eventsGrade 3 eventsGrade 4 eventsTreatment-related deathsDiscontinuation of treatmentMetastatic solid tumorsPhase 1 studyDurable clinical responsesBiomarkers of responseKRAS G12C mutationAssessment of safetyVariant allele frequencyClinical responseColorectal cancerSerial assessmentDose reductionG12C inhibitorsPatientsTumor DNA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply